Tenoxicam: NSAID and COX Inhibitor Overview
Explore the pharmacological properties and mechanisms of action of tenoxicam, a nonsteroidal anti-inflammatory drug (NSAID) belonging to the enolic acid derivative class. Learn how tenoxicam inhibits COX enzymes, reduces prostaglandin synthesis, and manages pain and inflammation associated with conditions like osteoarthritis and rheumatoid arthritis.
Recommended next
12 questions ready
Start with a quiz
Answer from memory first, then use the existing quiz review flow for anything you miss.
Activities
Quiz12 Questions
Study Notes1 Note
Podcast1 Episode
Modules
Learn in sequence
Start with the earlier modules and work forward. Each one builds on the last, so the course gets more advanced as you go.
Tenoxicam: NSAID and COX Inhibitor Overview
Quiz • 12 Questions
Study Notes
3 min • Summary
Tenoxicam: NSAID and COX Inhibitor Overview - Podcast
Podcast
Materials
List of Questions12 questions
- Question 1
- Activating cyclooxygenase (COX)-1 and -2
- Increasing thromboxane A2 production
- Inhibiting prostaglandins synthesis
- Reducing prostacycline levels
- Question 2
- It has similar side effects
- It causes more side effects
- It doesn't affect side effects
- It causes fewer side effects
- Question 3
- Migraine
- Diabetes
- Hypertension
- Osteoarthritis
- Question 4
- Prostaglandins
- Enolic acid derivatives
- Thromboxanes
- Steroids
- Question 5
- Glycogen synthase kinase-3 (GSK-3)
- Cyclooxygenase (COX)
- Aromatase
- Lipoxygenase (LOX)
- Question 6
- Activating thromboxane A2 production
- Enhancing prostacycline levels
- Blocking COX enzymes
- Increasing prostaglandins synthesis
- Question 7
- Enhanced vascular permeability
- Inhibition of platelet aggregation
- Reduced prostaglandin production
- Interference with kidney function
- Question 8
- Promoting prostaglandin production
- Increasing platelet aggregation
- Reducing vascular permeability
- Interfering with platelet aggregation
- Question 9
- 80% to 90%
- 98% to 102%
- 60% to 70%
- 50% to 55%
- Question 10
- Headaches
- Increased risk of bleeding
- Blurred vision
- Dizziness
- Question 11
- Patients with liver problems
- Patients on anticoagulant therapy
- Patients with gastrointestinal issues
- Patients with allergic reactions
- Question 12
- Mainly in adipose tissue
- Localized only in the liver
- Widely throughout the tissues
- Primarily in the kidneys